Furthermore, intratumoral administration of L19-TNF together with L19-IL2 in inoperable stage IIIC and IVM1a metastatic melanoma induced systemic antitumor immunity, resulting in complete responses in 53.8% of 13 non-injected lesions (70). Here, IL2 is linked to metastatic melanoma.